View in EDS

Human embryonic stem cell-derived cardiomyocyte platform screens inhibitors of SARS-CoV-2 infection

Saved in:
Bibliographic Details
Title: Human embryonic stem cell-derived cardiomyocyte platform screens inhibitors of SARS-CoV-2 infection
Authors: Williams, Thomas L., Colzani, Maria T., Macrae, Robyn G. C., Robinson, Emma L., Bloor, Stuart, Greenwood, Edward J. D., Zhan, Jun Ru, Strachan, Gregory, Kuc, Rhoda E., Nyimanu, Duuamene, Maguire, Janet J., Lehner, Paul J., Sinha, Sanjay, Davenport, Anthony P.
Contributors: DSpace at Cambridge pro (8.1)
Source: Commun Biol
Communications Biology, Vol 4, Iss 1, Pp 1-8 (2021)
Publisher Information: Springer Science and Business Media LLC, 2021.
Publication Year: 2021
Subject Terms: Benztropine, 631/154/436, QH301-705.5, SARS-CoV-2, Human Embryonic Stem Cells, article, Drug Evaluation, Preclinical, 631/532/2440, 14, Antiviral Agents, Article, 3. Good health, Humans, Myocytes, Cardiac, Biology (General), 14/19, Peptides
Description: Patients with cardiovascular comorbidities are more susceptible to severe infection with SARS-CoV-2, known to directly cause pathological damage to cardiovascular tissue. We outline a screening platform using human embryonic stem cell-derived cardiomyocytes, confirmed to express the protein machinery critical for SARS-CoV-2 infection, and a SARS-CoV-2 spike-pseudotyped virus system. The method has allowed us to identify benztropine and DX600 as novel inhibitors of SARS-CoV-2 infection in a clinically relevant stem cell-derived cardiomyocyte line. Discovery of new medicines will be critical for protecting the heart in patients with SARS-CoV-2, and for individuals where vaccination is contraindicated.
Document Type: Article
Other literature type
File Description: application/pdf; application/vnd.openxmlformats-officedocument.wordprocessingml.document; application/zip; text/xml
Language: English
ISSN: 2399-3642
DOI: 10.1038/s42003-021-02453-y
DOI: 10.17863/cam.74830
DOI: 10.17863/cam.71514
DOI: 10.17863/cam.73505
Access URL: https://www.nature.com/articles/s42003-021-02453-y.pdf
https://pubmed.ncbi.nlm.nih.gov/34326460
https://doaj.org/article/38772e0bff5a4477befd0ea1c3205005
https://www.repository.cam.ac.uk/handle/1810/327376
https://aspace.repository.cam.ac.uk/handle/1810/327376
https://www.repository.cam.ac.uk/handle/1810/327376
https://doi.org/10.1038/s42003-021-02453-y
https://doi.org/10.17863/cam.74830
Rights: CC BY
URL: http://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (http://creativecommons.org/licenses/by/4.0/) .
Accession Number: edsair.doi.dedup.....902f4cf437b83bb5a306aec8cc48bf5c
Database: OpenAIRE
Description
Abstract:Patients with cardiovascular comorbidities are more susceptible to severe infection with SARS-CoV-2, known to directly cause pathological damage to cardiovascular tissue. We outline a screening platform using human embryonic stem cell-derived cardiomyocytes, confirmed to express the protein machinery critical for SARS-CoV-2 infection, and a SARS-CoV-2 spike-pseudotyped virus system. The method has allowed us to identify benztropine and DX600 as novel inhibitors of SARS-CoV-2 infection in a clinically relevant stem cell-derived cardiomyocyte line. Discovery of new medicines will be critical for protecting the heart in patients with SARS-CoV-2, and for individuals where vaccination is contraindicated.
ISSN:23993642
DOI:10.1038/s42003-021-02453-y